Clinical, Cognitive, and Neurophysiologic Correlates of Short-Term Treatment with Carbamazepine, Oxcarbazepine, and Levetiracetam in Healthy Volunteers

BACKGROUND The adverse effects of the antiepileptic drugs (AEDs) originally developed are well known, while those of the newer AEDs remain unclear. OBJECTIVE To investigate clinical, cognitive, and neurophysiologic effects of carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. METHODS A double-blind crossover study was conducted in 10 volunteers. Eight-day treatment with carbamazepine, oxcarbazepine, levetiracetam, or placebo was administered in random order. Drug doses were titrated gradually to the daily target doses on day 7: carbamazepine 800 mg, oxcarbazepine 1200 mg, and levetiracetam 1500 mg. At baseline and at the end of each treatment period, participants underwent cognitive and neurophysiologic assessment. A washout period of 14 days between treatment periods was conducted. RESULTS More adverse events were self-reported with carbamazepine (63%) than the other treatments (oxcarbazepine 12%, levetiracetam 20%, placebo 5%; p < 0.001 between the 4 groups). Carbamazepine induced the greatest motor slowing (p = 0.002), followed by oxcarbazepine (p = 0.01). Levetiracetam left baseline motor speed unchanged. All AEDs increased attention span from baseline values as shown on the Stroop test. Quantitative electroencephalogram (EEG) analysis showed that carbamazepine significantly increased the delta–theta power and reduced the frequency of alpha rhythm; oxcarbazepine induced smaller changes than carbamazepine. Levetiracetam did not change any EEG measurements. On color visually evoked potential (VEP) tests, carbamazepine induced a constant slowing of P1 latency, while oxcarbazepine induced changes only after the blue–black pattern. All color VEP measures for volunteers receiving levetiracetam were almost unchanged. CONCLUSIONS After short-term treatment in healthy volunteers, carbamazepine induced major clinical and neurophysiologic changes. Oxcarbazepine was better tolerated than carbamazepine. Levetiracetam interfered least with clinical and neurophysiologic test results.

[1]  A. Korczyn,et al.  Comparison of the effects of vigabatrin, lamotrigine, and topiramate on quantitative EEGs in patients with epilepsy. , 1999, Clinical neuropharmacology.

[2]  N. Accornero,et al.  Changes in Color Vision after a Single Dose of Vigabatrin or Carbamazepine in Healthy Volunteers , 2001, Clinical neuropharmacology.

[3]  A. Aldenkamp,et al.  Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  Yung-Jung Chen,et al.  Comparison of Antiepileptic Drugs on Cognitive Function in Newly Diagnosed Epileptic Children: A Psychometric and Neurophysiological Study , 1996, Epilepsia.

[5]  K. Meador,et al.  Cognitive and Behavioral Effects of Epilepsy Treatment , 2001, Epilepsia.

[6]  K. Meador,et al.  Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults , 1995, Neurology.

[7]  N. Accornero,et al.  A new color vep procedure discloses asymptomatic visual impairments in optic neuritis and glaucoma suspects , 2000, Acta neurologica Scandinavica.

[8]  A. Marson,et al.  Neuropsychological Outcomes in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards , 1998, Epilepsia.

[9]  N. Accornero,et al.  Clinical and Electroencephalographic Effects of Topiramate in Patients with Epilepsy and Healthy Volunteers , 2001, Clinical neuropharmacology.

[10]  J. Partanen,et al.  Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects , 1999, Neurology.

[11]  H. Curran,et al.  Memory and psychomotor effects of oxcarbazepine in healthy human volunteers , 2006, European Journal of Clinical Pharmacology.

[12]  Jullie W Pan,et al.  Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults , 1999, Neurology.

[13]  J. Cramer,et al.  A systematic review of the safety profile of levetiracetam: a new antiepileptic drug , 2001, Epilepsy Research.

[14]  A. Aldenkamp,et al.  Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research , 1995, Epilepsy Research.

[15]  Daniel Storzbach,et al.  Assessment of CNS Effects of Antiepileptic Drugs by Using Quantitative EEG Measures , 2003, Epilepsia.

[16]  D W King,et al.  Effects of Carbamazepine and Phenytoin on EEG and Memory in Healthy Adults , 1993, Epilepsia.

[17]  A. Aldenkamp,et al.  Newer Antiepileptic Drugs and Cognitive Issues , 2003, Epilepsia.

[18]  K. Goa,et al.  Oxcarbazepine: an update of its efficacy in the management of epilepsy. , 2001, CNS drugs.

[19]  Daniel Storzbach,et al.  Effects of Gabapentin and Carbamazepine on the EEG and Cognition in Healthy Volunteers , 2002, Epilepsia.

[20]  J. Arends,et al.  Randomized Double‐blind Parallel‐group Study Comparing Cognitive Effects of a Low‐dose Lamotrigine with Valproate and Placebo in Healthy Volunteers , 2002, Epilepsia.

[21]  M. A. Bassetti,et al.  Lamotrigine Add‐On Therapy in Focal Epilepsy: Electroencephalographic and Neuropsychological Evaluation , 1998, Clinical neuropharmacology.